CION Ameerpet
There is no single price for ovarian cancer treatment, and any figure quoted over the phone before someone has read your reports is a guess. The number is assembled from parts — the operation, the chemotherapy course, maintenance treatment afterwards, and the scans and tests alongside. This page shows you the parts, so the estimate you are handed stops being a mystery.
There is no single price. The honest way to think about ovarian cancer treatment cost in Hyderabad is as four blocks added together: the operation, the chemotherapy course, maintenance treatment afterwards, and the scans and tests that run alongside all of it. Each block has its own range, and each moves for a different reason.
Two of those blocks surprise people. The first is maintenance therapy, which begins after the drama is over and runs quietly for months — for some women it is the largest line in the whole budget. The second is that the operation is usually not billed by us. Cytoreductive surgery, HIPEC, intraperitoneal chemotherapy and PET-CT are delivered at specialist gynaecologic-oncology partner centres and may be billed there. You should know that on the first day rather than the last.
What follows is an itemised view of each block, drawn from CION's own published indicative ranges, and the questions that stop an estimate from quietly doubling. If you want the clinical picture rather than the financial one, the complete ovarian cancer guide covers symptoms, stages, treatment and outcomes.
Ovarian cancer is treated over months: surgery, several cycles of chemotherapy, then often maintenance. Budget for the sequence, not for the admission.
How much disease there is decides how long the operation takes, whether intensive care is needed, and how much treatment follows it.
Surgery, HIPEC and PET-CT sit at partner centres and are billed there. Chemotherapy, maintenance and testing are delivered in-house at CION.
Ovarian cancer surgery, chemotherapy and supportive care are listed as defined treatment packages under Ayushman Bharat PM-JAY, which provides ₹5 lakh per family per year of cashless cover at empanelled hospitals — delivered in Telangana alongside Aarogyasri and in Andhra Pradesh alongside NTR Vaidya Seva, whose own limits are set by the state. The detail that catches families out is the wording: cover is per family, per year, not per admission. A relative's earlier claim reduces what is left, and a course of treatment that runs across two financial years draws on two years of entitlement. Check the balance before admission, not after. Source: National Health Authority, Ayushman Bharat PM-JAY health benefit packages.
These are CION's published indicative ranges, shown as parts rather than as one total. Your own figure is written after staging, and will usually sit somewhere inside these bands rather than at either end.
| Part of treatment | Indicative range | What moves it |
|---|---|---|
| Cytoreductive (debulking) surgery | ₹2,50,000 – ₹9,00,000 | Extent of disease, length of the operation, bowel or diaphragm involvement, intensive-care stay. Delivered at a specialist partner centre and may be billed there. |
| Chemotherapy, full course | ₹1,50,000 – ₹7,00,000 | Number of cycles, the regimen, day-care versus admission, pre-treatment blood tests and supportive injections. |
| Maintenance therapy, over months | ₹2,00,000 – ₹15,00,000 | Drug class and duration. Split between PARP-inhibitor-class maintenance and anti-angiogenic maintenance, both priced per month. |
| Supportive and allied care | ₹40,000 – ₹2,00,000 | Anti-sickness medication, blood-count support, transfusions, nutrition input and physiotherapy across the treatment months. |
| Room category, per admission | Semi-private ₹15,000 – ₹40,000 · Private ₹40,000 – ₹90,000 | Your choice of room and the length of stay. General ward is included in most scheme packages. |
| Whole-body PET-CT, where indicated | ₹9,999 analog · ₹14,950 digital | Published CION price. Analog or digital scanner; digital resolves smaller deposits. Not needed in every case. |
| HIPEC or intraperitoneal chemotherapy | Quoted per case at the partner centre | Only for selected women at interval surgery. Sits on top of the surgical package and is billed by the partner centre. |
| BRCA and HRD testing | Quoted per test when ordered | Germline blood test, tumour panel, or both. Small in itself, but it decides eligibility for the maintenance line above. |
*Indicative ranges drawn from CION's published ovarian cancer cost estimator. They are not a quotation and not a package price. Surgery, HIPEC, intraperitoneal chemotherapy and PET-CT are delivered at specialist partner centres and may be billed there. Your written estimate is issued after assessment.
Two women with the same diagnosis can end the year lakhs apart. These are the seven things that explain the gap, roughly in order of how much they matter.
Stage is the single biggest driver, because it decides how big the operation is. Early disease confined to one ovary may need a staging operation and a shorter course of chemotherapy. Advanced disease spread across the abdomen may need a long cytoreductive operation involving bowel, diaphragm or peritoneum, a stay in intensive care, and a full course of chemotherapy afterwards.
This is why an estimate given before staging is complete is always provisional. Until imaging and, often, the operation itself show how much disease there is, the surgical component carries a wide band around it. Debulking surgery cost sets out what sits inside that band.
Some women have surgery first and chemotherapy after. Others have chemotherapy first to shrink the disease, then interval surgery, then more chemotherapy. The total number of cycles is often similar, but the sequence changes when the money is spent and can change how long the hospital stay is.
The sequence is a clinical decision, never a financial one — it is chosen on how much disease there is and how fit you are for a long operation. It does affect cash flow, though, so it is worth asking which pathway is planned. That lets you budget for the next three months rather than the next three weeks.
A standard course of platinum-based chemotherapy runs over several cycles, usually three weeks apart. The drug is only part of the line. Each cycle also carries day-care charges, pre-medication, blood tests before treatment is cleared, and sometimes supportive injections to keep blood counts up.
Day-care chemotherapy at a centre near home costs less in every sense than repeated admissions to one city hospital: less travel, fewer nights, less time off work for whoever comes with you. Chemotherapy cost for ovarian cancer breaks a single cycle down.
After chemotherapy, many women continue on maintenance treatment to delay the cancer returning. It is taken for months and sometimes years, which makes it the largest single line in the budget for some women, even though nothing dramatic is happening.
Eligibility depends partly on your BRCA and HRD result, so a genomic test costing a few thousand rupees decides a line worth lakhs. Two classes are used, each priced per month rather than per course: PARP-inhibitor-class maintenance and anti-angiogenic maintenance therapy. Ask which is planned, and for how many months, before treatment starts.
HIPEC is heated chemotherapy delivered into the abdomen during surgery, used in selected women at interval debulking. Intraperitoneal chemotherapy delivers drug into the abdominal cavity through a port in the weeks afterwards. Neither is standard for everyone, and neither should be added to a plan simply because it is available.
Both are delivered at specialist partner centres and billed there, on top of the surgical package. If HIPEC has been proposed for you, ask what it is expected to add and why your case fits the selection criteria. HIPEC cost for ovarian cancer sets out what a quote usually includes.
Imaging and pathology are a modest share of the total, but they recur: a CT at diagnosis, sometimes a PET-CT where the extent of disease is unclear, CA-125 through treatment, and imaging again at the end. CION publishes PET-CT prices openly rather than on request — whole-body analog at ₹9,999 and digital at ₹14,950.
Two habits save money at no clinical cost. Carry your original films and reports to every opinion, so scans are read rather than repeated. And ask of any proposed test what it will change — a scan whose result cannot alter the plan is a scan you do not need. PET-CT cost and BRCA and genetic testing cost cover these individually.
The same treatment plan produces very different out-of-pocket numbers depending on how it is funded. Eligible treatment at an empanelled centre under Aarogyasri, PM-JAY or NTR Vaidya Seva can be largely covered. A private policy with cashless approval covers most of an admission but often treats consumables and outpatient drugs differently.
Self-payment is where the full range applies, and where instalment options matter. Whichever applies to you, the eligibility check belongs before admission rather than after. A claim queried later is far harder to fix than one approved in advance, and the paperwork takes days, not hours.
None of these is an accusation, and no good centre minds being asked. They exist because the commonest reason an estimate doubles is not overcharging — it is a line nobody costed.
A package has fixed inclusions and a defined stay. An estimate does not. Ask which you have been handed, and what happens to the figure if the stay runs longer.
Surgery, HIPEC and PET-CT are delivered at specialist partner centres and billed there. Knowing that before admission prevents a shock afterwards.
Quotes are often per cycle. Multiply by the planned cycles, and ask whether pre-treatment blood tests and supportive injections sit inside or outside the figure.
It runs for months after the last cycle and is priced monthly. An estimate that stops at the end of chemotherapy is not an estimate of your treatment.
A fair question, asked politely. If the plan is the same either way, the scan can usually wait. No unnecessary tests is a working rule, not a slogan.
Aarogyasri, PM-JAY and NTR Vaidya Seva approvals are arranged before admission. Ask for confirmation in writing, and ask what the package excludes.
Ask these once, in writing, before treatment starts. A centre that answers them plainly is telling you something useful about how the rest of your care will be handled.
Bring your scan and biopsy reports to a free 45-minute consultation. You leave with an itemised estimate: what is done in-house, what is coordinated at a partner centre and billed there, and what your scheme or insurance is likely to absorb.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them - together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
The first consultation is free and there is no obligation. If a shorter or less expensive pathway is right for you, we will say so — and if part of your care belongs at a partner centre, you will know before you pay anything.
An estimate is only as good as the plan behind it. This is the order in which the plan — and therefore the number — is settled at CION.
Bring every scan, biopsy report and discharge summary you have. Most of what determines cost is already in those papers: how much disease there is, what has been done, and what remains. The first consultation at CION is free, and no estimate is worth much before someone has read them properly.
Staging decides the size of the operation and the length of treatment, so it has to be right. It does not require a panel of everything. Where an outside scan is recent and adequate, it is read rather than repeated, and a test is ordered only when its result would change what happens next.
Medical oncology, imaging, pathology and the surgical team review the same case together. The sequence they agree — surgery first or chemotherapy first, how many cycles, whether maintenance is likely — is what fixes the shape of the bill. The cost follows the plan; it never leads it.
Whether you are covered under Aarogyasri, PM-JAY, NTR Vaidya Seva, CGHS, ECHS, ESI or a private policy, the approval belongs in place before you are admitted. Our team checks eligibility, prepares the paperwork and tells you what the scheme package leaves outside it.
In-house lines and partner-centre lines shown separately, with the expected number of chemotherapy cycles, an indication of maintenance if it is likely, and what falls outside the package. If a line is uncertain because staging is not complete, it says so rather than quietly omitting it.
Plans change. The operation finds more or less disease than imaging suggested, or a cycle is delayed for blood counts. When the plan moves, ask for the estimate to be revised at that point — not to discover the change on the final bill.
*Every estimate remains indicative until staging is complete. Cost figures are not a quotation, and eligible scheme cover is confirmed by the scheme, not by us.
Almost nobody pays for ovarian cancer treatment out of one pocket. Most families use a combination — a state scheme for the admissions, insurance for part of the rest, savings for the outpatient drugs, and instalments for what is left. Knowing which cover applies to which part is what keeps the total manageable.
Under Aarogyasri in Telangana, NTR Vaidya Seva in Andhra Pradesh and Ayushman Bharat PM-JAY nationally, eligible ovarian cancer treatment at an empanelled centre may be largely covered. Cover is granted per family per year, so it is worth knowing what a relative's earlier claim has already used, and whether your treatment will cross into a new year part-way through.
Private insurance usually works cashless at a network hospital when approval is obtained before admission. Read the waiting-period and pre-existing-disease clauses rather than assuming, and ask specifically about day-care chemotherapy and outpatient maintenance drugs, which some policies treat differently from an inpatient admission. CGHS, ECHS and ESI each have their own empanelment and referral route, and the referral has to be raised in advance.
For eligible families in Telangana, treatment at an empanelled centre may be largely covered. Approval is arranged before admission, and the general ward sits inside the package.
The Andhra Pradesh route for eligible families, working the same way: empanelled centre, pre-admission approval, defined packages for surgery and chemotherapy.
Cashless approval at a network hospital covers most of an admission. Check how your policy treats day-care chemotherapy and the months of outpatient maintenance.
Where treatment is self-funded, the chemotherapy and maintenance months can usually be spread rather than paid upfront. Ask before the first cycle, not after the third.
Bring your scheme card, policy document and any earlier claim details to the first consultation. Half of what delays an approval is paperwork that could have been assembled a week earlier.
Cost is the question most families are too polite to ask first and too worried not to ask at all. It should be answered in the same consultation as the diagnosis, in writing, with the uncomfortable parts included. Decisions for healing, not billing, is only meaningful if the billing is visible.
Your first consultation at CION is free and runs to about 45 minutes — long enough to read the reports you bring, explain what the proposed plan is trying to achieve, and cost it. Every case is discussed at a tumour board rather than decided by one doctor, and tests that would not change the plan are not ordered.
We should be plain about the division of work, because it decides who bills you. Cytoreductive surgery, HIPEC, intraperitoneal chemotherapy and PET-CT are coordinated with specialist gynaecologic-oncology partner centres and may be billed there. That is deliberate: this is an operation where specialist volume genuinely changes the result. Chemotherapy, maintenance therapy, genetic counselling, BRCA and HRD testing, nutrition support and follow-up are delivered in-house at CION, across 35+ centres in Telangana and Andhra Pradesh, which usually means the treatment months run near where you live rather than in one city hospital.
One last thing, since this is a page about money. The reason to ask what a plan costs is to weigh it against what it achieves. CION publishes its own one-year survival next to the national figure rather than implying a comparison: 81.0% of CION ovarian cancer patients are alive at one year, against a national figure of 73.7%. That is a one-year figure across a treated population — not a cure rate, and not a prediction for you.
Free and unhurried. Long enough to read your reports, explain the plan and put a number against it before you decide anything.
Medical oncology, imaging, pathology and the surgical team agree the sequence. The plan is what fixes the cost, so it is worth getting right once.
Performed by specialist gynaecologic-oncology surgeons at partner centres and may be billed there. Stated upfront, not discovered at discharge.
Chemotherapy, maintenance and follow-up run at CION centres across Telangana and Andhra Pradesh, which takes travel and time off work out of the real cost.
*One-year survival rates. CION figures reflect CION's treated patient population; national figures are drawn from published Indian cancer registry data. Survival statistics describe groups, not individuals. All cost figures on this page are indicative and are not a quotation.
There is no single figure, because treatment is a sequence rather than one procedure. Using CION's published indicative ranges, cytoreductive surgery falls between ₹2,50,000 and ₹9,00,000, a full chemotherapy course between ₹1,50,000 and ₹7,00,000, maintenance therapy between ₹2,00,000 and ₹15,00,000 depending on class and duration, and supportive care between ₹40,000 and ₹2,00,000. A semi-private or private room adds to each admission. Those bands are indicative, not a quotation. The number that matters is the itemised estimate written after your stage is known and the plan is agreed at a tumour board. Eligible treatment at an empanelled centre under Aarogyasri, PM-JAY or NTR Vaidya Seva reduces the out-of-pocket figure substantially, and surgery is delivered at a specialist partner centre and may be billed there.
Ovarian cancer surgery, chemotherapy and supportive care are listed as defined packages under Ayushman Bharat PM-JAY, which provides five lakh rupees per family per year of cashless cover at empanelled hospitals. In Telangana the benefit is delivered alongside Aarogyasri, and in Andhra Pradesh alongside NTR Vaidya Seva, each with its own eligibility rules and limits set by the state. Two details matter in practice. Cover is per family per year, not per admission, so a relative's earlier claim reduces what is left to you. And approval has to be arranged before admission at an empanelled centre, not claimed afterwards. Our team checks eligibility, prepares the paperwork and tells you plainly what the package leaves outside it, such as certain consumables and outpatient drugs.
Because it is priced by the month and continues long after the visible treatment has finished. Maintenance therapy is given after chemotherapy to delay the cancer coming back, and it is taken for months and sometimes years. Nothing dramatic happens during that time, which is exactly why estimates written around the admission tend to leave it out entirely. Whether you are offered it, which class is used and for how long depends partly on your BRCA and HRD result, so a genomic test costing a few thousand rupees decides a line worth lakhs. Ask for maintenance to be costed at the start, with the expected duration stated, rather than finding out about it when chemotherapy ends.
Usually yes for admissions, provided the hospital is in your insurer's network and approval is obtained before you are admitted. The parts that catch people out sit outside the admission. Day-care chemotherapy, outpatient maintenance drugs, genomic testing and some consumables are treated differently by different policies, and a policy that covers hospitalisation generously may cover these thinly. Read the waiting-period and pre-existing-disease clauses rather than assuming, and get the pre-authorisation in writing. If you also hold a scheme entitlement, ask which should be used first. Bring the policy document to the first consultation, so the claim is built alongside the treatment plan rather than chased after it.
Often not. In advanced ovarian cancer, how much visible disease is left at the end of the operation is one of the strongest predictors of how the rest of treatment goes, and complete removal with no visible residual disease is the recognised goal in international guidance including NCCN. An operation that leaves disease behind tends to be followed by more treatment rather than less, so a lower surgical quote can cost more across the year. This is why surgery is coordinated with specialist gynaecologic-oncology surgeons at partner centres rather than done wherever is nearest or cheapest: specialist volume genuinely changes what the operation achieves. Compare pathways over twelve months, not admissions over five days.
A typical pathway includes a pelvic ultrasound, CA-125, a CT of the abdomen and pelvis for staging, histopathology after surgery, and BRCA and HRD testing to decide maintenance. PET-CT is used in selected cases where the extent of disease is unclear or recurrence is suspected, and CION publishes its prices openly at ₹9,999 for a whole-body analog scan and ₹14,950 for digital. Two things reduce the total without costing you anything clinically. Carry your original films and reports to every consultation, so recent scans are read rather than repeated. And ask of any proposed test what it will change — if the plan is the same either way, it can usually wait.
The first consultation is free and runs to about 45 minutes. CION delivers medical oncology for ovarian cancer in-house: chemotherapy, maintenance therapy, genetic counselling, BRCA and HRD testing, nutrition support and follow-up, across more than 35 centres in Telangana and Andhra Pradesh. Cytoreductive surgery, HIPEC, intraperitoneal chemotherapy and PET-CT are coordinated with specialist gynaecologic-oncology partner centres and may be billed there, and we say so upfront rather than leaving it to be discovered at discharge. Every case is reviewed at a tumour board before a plan is set, and you leave the first visit with an itemised written estimate showing in-house and partner-centre lines separately.